Targeting specific changes in a cancer-related gene in stomach and esophagus cancer
Targeting FGFR Alterations in Gastroesophageal Cancer
This study is looking at new ways to treat stomach and esophagus cancer for patients with certain changes in their FGFR2 gene, by combining regular chemotherapy with special targeted treatments to help improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10999105 on NIH RePORTER |
What this research studies
This research focuses on gastroesophageal adenocarcinoma, a type of cancer affecting the stomach and esophagus, particularly in patients with specific alterations in the FGFR2 gene. The study aims to explore new treatment options that combine standard chemotherapy with targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, to improve patient outcomes. By investigating the mechanisms of resistance to current treatments, the research seeks to develop innovative combination therapies that may enhance effectiveness against this aggressive cancer. Patients may be involved in clinical trials assessing these new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gastroesophageal adenocarcinoma who exhibit FGFR2 gene alterations.
Not a fit: Patients without gastroesophageal adenocarcinoma or those whose cancer does not involve FGFR2 alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with gastroesophageal adenocarcinoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous clinical trials targeting FGFR2 in gastroesophageal cancer have shown promising results, indicating that this approach has potential based on earlier successes.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Ryeom, Sandra — Columbia University Health Sciences
- Study coordinator: Ryeom, Sandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.